8VE5

(Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the compressed conformation

Summary for 8VE5

• Entry DOI: 10.2210/pdb8ve5/pdb
• EMDB information: 43165
• Descriptor: Transthyretin, 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID (2 entities in total)
• Functional Keywords: amyloidosis, transport protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 4
• Total formula weight: 63940.15

Authors

Basanta, B.,Nugroho, K.,Yan, N.,Kline, G.M.,Tsai, F.J.,Wu, M.,Kelly, J.W.,Lander, G.C. (deposition date: 2023-12-18, release date: 2024-06-05, Last modification date: 2025-02-05)

Primary citation

Basanta, B.,Nugroho, K.,Yan, N.L.,Kline, G.M.,Powers, E.T.,Tsai, F.J.,Wu, M.,Hansel-Harris, A.,Chen, J.S.,Forli, S.,Kelly, J.W.,Lander, G.C.
The conformational landscape of human transthyretin revealed by cryo-EM.
Nat.Struct.Mol.Biol., 2025

PubMed Abstract: Transthyretin (TTR) is a natively tetrameric thyroxine transporter in blood and cerebrospinal fluid whose misfolding and aggregation causes TTR amyloidosis. A rational drug design campaign identified the small molecule tafamidis (Vyndamax) as a stabilizer of the native TTR fold, and this aggregation inhibitor is regulatory agency approved for the treatment of TTR amyloidosis. Here we used cryo-EM to investigate the conformational landscape of this 55 kDa tetramer in the absence and presence of one or two ligands, revealing inherent asymmetries in the tetrameric architecture and previously unobserved conformational states. These findings provide critical mechanistic insights into negatively cooperative ligand binding and the structural pathways responsible for TTR amyloidogenesis, underscoring the capacity of cryo-EM to identify pharmacological targets suppressed by the confines of the crystal lattice, opening uncharted territory in structure-based drug design.

PubMed: 39843982
DOI: 10.1038/s41594-024-01472-7

Experimental method

ELECTRON MICROSCOPY (3.4 Å)